Buscar en
Archivos de la Sociedad Española de Oftalmología (English Edition)
Toda la web
Inicio Archivos de la Sociedad Española de Oftalmología (English Edition) Intracameral bevacizumab (Avastin®) in the management of neovascular glaucoma s...
Journal Information
Vol. 87. Issue 12.
Pages 396-400 (December 2012)
Share
Share
Download PDF
More article options
Visits
1917
Vol. 87. Issue 12.
Pages 396-400 (December 2012)
Original article
Intracameral bevacizumab (Avastin®) in the management of neovascular glaucoma surgery
Bevacizumab (Avastin®) intracamerular en el manejo quirúrgico del glaucoma neovascular
Visits
1917
H. Fernández Jiménez-Ortiz
Corresponding author
hector_fernan@hotmail.com

Corresponding author.
, S. Perucho Martinez, N. Toledano Fernández, E. Martin Giral
Servicio de Oftalmología, Hospital Universitario de Fuenlabrada, Madrid, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (3)
Table 1. Characteristics of study cases.
Table 2. Intraocular pressure prior to bevacizumab and at weeks 1 and 4.
Table 3. Maximum corrected visual acuity and rubeosis iridis prior to bevacizumab and after one and 4 weeks.
Show moreShow less
Abstract
Purpose

To describe a case series of neovascular glaucoma treated with intracameral bevacizumab prior to filtering surgery.

Design

Descriptive, retrospective case series.

Methods

Five eyes of 5 patients with neovascular glaucoma due to any cause candidates to filtering surgery who had previously received an injection of intracameral bevacizumab (1.25mg/0.05ml) as treatment for neovascularization of anterior chamber. Results observed one week and 4 weeks post-surgery are reported.

Results

Bevacizumab produced regression of the angle neovascularization and the intraocular pressure. Only one case of postoperative bleeding was detected.

Conclusions

Intracameral bevacizumab prior to filtering surgery of neovascular glaucoma diminished the neovascularization and intraocular pressure after 4 weeks of its administration and was effective in preventing intraoperative and postoperative bleeding. It also constitutes a promising way of investigation to prevent surgical complications.

Keywords:
Bevacizumab
Glaucoma neovascular
Filtering surgery
Angiogenesis inhibitors
Injections intraocular
Resumen
Propósito

Describir una serie de casos con glaucoma neovascular que fueron tratados con bevacizumab intracamerular previo a la cirugía filtrante.

Diseño

Descriptivo, retrospectivo, tipo serie de casos.

Métodos

Cinco ojos de cinco pacientes con glaucoma neovascular de cualquier causa candidatos a cirugía filtrante recibieron previamente una inyección de bevacizumab (1,25mg/0,05ml) intracamerular como tratamiento de la neovascularización angular. Se describen los resultados observados a la semana y a las 4 semanas poscirugía.

Resultados

Bevacizumab produjo una regresión importante de los neovasos y de la presión intraocular. Se detectó un único caso de sangrado postoperatorio.

Conclusiones

Bevacizumab intracamerular previo a cirugía filtrante de glaucoma disminuyó la neovascularización del segmento anterior y la presión intraocular a las 4 semanas de su administración y resultó eficaz en impedir el sangrado intra- y postoperatorio. También constituye una prometedora vía de investigación para prevenir las complicaciones quirúrgicas.

Palabras clave:
Bevacizumab
Glaucoma neovascular
Cirugía filtrante
Antiangiogénicos
Inyección intraocular

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de la Sociedad Española de Oftalmología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos